Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.74% | -56.95% | 23.91% | -13.42% | 0.24% |
| Total Depreciation and Amortization | 2.08% | -0.15% | -4.13% | -5.73% | 8.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.18% | 28.44% | -38.37% | 49.87% | -20.11% |
| Change in Net Operating Assets | -98.93% | 351.49% | 61.48% | -348.03% | -25.93% |
| Cash from Operations | -9.19% | 15.56% | 34.96% | -109.89% | -18.39% |
| Capital Expenditure | 26.60% | 48.05% | -85.80% | -712.27% | 89.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.20% | 60.87% | -39.25% | 18.07% | 137.49% |
| Cash from Investing | -161.65% | 64.64% | -40.63% | 16.96% | 137.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 109,500.00% | -100.00% | 53,179.62% | -94.67% | -29.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | 19,709,500.00% | -100.00% | 53,179.62% | -94.67% | -73.64% |
| Foreign Exchange rate Adjustments | -323.13% | -89.91% | 101.24% | 174.33% | -252.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 749.97% | -47.33% | 209.97% | -285.98% | 107.33% |